Literature DB >> 18353532

Telephonic guidance of systemic thrombolysis in acute ischemic stroke: safety outcome in rural hospitals.

Anand G Vaishnav1, L Creed Pettigrew, Stephen Ryan.   

Abstract

OBJECTIVES: To determine the safety of telephonic guidance for use of intravenous recombinant tissue plasminogen activator (IV rtPA) in rural hospitals. PATIENTS AND METHODS: We performed a retrospective survey of 123 consecutive patients treated with IV rtPA for acute ischemic stroke (AIS) in rural hospitals between November 2003 and September 2006 and subsequently transferred to a tertiary medical center. Selection for treatment was performed by a stroke neurologist who conducted a structured telephone interview of the requesting physician. Primary outcome measures included symptomatic intracerebral hemorrhage (ICH) and in-hospital mortality.
RESULTS: Elapsed time (ET) from stroke onset to community hospital arrival was 54+/-30 min. ET from stroke onset to tPA bolus was 133+/-37 min. Three patients (2.5%) had symptomatic ICH, 11 (9%) had asymptomatic ICH, 9 patients (7.5%) died. Mean length of stay was 4+/-3 days; 47% were discharged to their homes. Mean ET from stroke onset to rtPA dosage did not differ significantly from the active treatment group of the NINDS rtPA Stroke Study. Prevalence of symptomatic ICH and mortality were lower in our population.
CONCLUSION: We conclude that telephonic guidance of rtPA treatment is safe, practical, and effective in overcoming barriers for optimal care of AIS in rural communities.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18353532     DOI: 10.1016/j.clineuro.2008.01.010

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  8 in total

Review 1.  Telemedicine or telephone consultation in patients with acute stroke.

Authors:  Bart M Demaerschalk
Journal:  Curr Neurol Neurosci Rep       Date:  2011-02       Impact factor: 5.081

2.  Implementation of Telemedicine and Stroke Network in thrombolytic administration: comparison between walk-in and referred patients.

Authors:  Pornpatr A Dharmasaroja; Sombat Muengtaweepongsa; Urai Kommarkg
Journal:  Neurocrit Care       Date:  2010-08       Impact factor: 3.210

3.  Intermittent Broca's aphasia management in an emergency unit: from theory to practice.

Authors:  Alberto Mazza; Roberto L'erario; Roberta Ravenni; Domenico Montemurro; Pietro Amistà; Silvio Aggio; Francesco Zanon
Journal:  Neurol Sci       Date:  2011-09-07       Impact factor: 3.307

Review 4.  Enhancing community delivery of tissue plasminogen activator in stroke through community-academic collaborative clinical knowledge translation.

Authors:  Phillip A Scott
Journal:  Emerg Med Clin North Am       Date:  2009-02       Impact factor: 2.264

Review 5.  Early identification and delay to treatment in myocardial infarction and stroke: differences and similarities.

Authors:  Johan Herlitz; Birgitta Wireklintsundström; Angela Bång; Annika Berglund; Leif Svensson; Christian Blomstrand
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2010-09-06       Impact factor: 2.953

Review 6.  The chain of care enabling tPA treatment in acute ischemic stroke: a comprehensive review of organisational models.

Authors:  Maarten M H Lahr; Gert-Jan Luijckx; Patrick C A J Vroomen; Durk-Jouke van der Zee; Erik Buskens
Journal:  J Neurol       Date:  2012-08-23       Impact factor: 4.849

Review 7.  Stroke telemedicine.

Authors:  Bart M Demaerschalk; Madeline L Miley; Terri-Ellen J Kiernan; Bentley J Bobrow; Doren A Corday; Kay E Wellik; Maria I Aguilar; Timothy J Ingall; David W Dodick; Karina Brazdys; Tiffany C Koch; Michael P Ward; Phillip C Richemont
Journal:  Mayo Clin Proc       Date:  2009       Impact factor: 7.616

8.  Cerebral Thrombolysis in Rural Residents Aged ≥ 80.

Authors:  Piotr Sobolewski; Waldemar Brola; Jacek Wilczyński; Wiktor Szczuchniak; Tomasz Wójcik; Aleksandra Wach-Klink; Marek Kos; Grzegorz Kozera
Journal:  Clin Interv Aging       Date:  2020-09-24       Impact factor: 4.458

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.